HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Immunomodulation in established murine tumors: response and survival rate enhancement by blood leukocyte-augmenting substance 236 (Cl-), a novel synthetic compound.

Abstract
Immunomodulation in cancer has obvious appeal. Available data suggest the central role to be played by the host immune response in cancer outcome. Herein, we report a novel compound, Blood Leukocyte Augmenting Substance 236 (Cl(-)) [BLAS 236 (Cl(-))], which is able to restore and/or strengthen immunocompetence, which is critical in host-resistance to malignancy. The effects of several protocols in which BLAS 236 (Cl(-)) was given as single-agent or combined therapy on established murine tumors were evaluated in terms of long-term tumor-free survivors (>1 year). Treatment significantly improved overall complete response and survival rates and prolonged the life span of mice to beyond that of animals receiving placebo. The most outstanding protocols (denoted B3, B6 and D6, D7), were able to flatten tumor-free survival curves at the 80% and 100% levels, respectively (P < 0.001 for each protocol); these results compare favorably with those reported for other preclinical trials. Immunomodulation by BLAS 236 (Cl(-)) is viewed as a new efficient, safe way of potentiating and maintaining host-resistance to malignancy that holds promise as an adjuvant therapy alternative to current immune approaches for the ultimate cure of cancer.
AuthorsSalomón Pérez Cuadrado, María del Carmen Moreno Koch, Cristina Fernández Pérez, Luis Miguel Castejón Castán, Carlos Pérez Villalobos, María José González Mateos, Carlos Liñán Olmos
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 9 Issue 15 Pg. 5776-85 (Nov 15 2003) ISSN: 1078-0432 [Print] United States
PMID14654563 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Adjuvants, Immunologic
  • BLAS 236
  • Placebos
  • Pyridines
  • Quaternary Ammonium Compounds
  • Cyclophosphamide
  • Pyrrolidonecarboxylic Acid
Topics
  • Adjuvants, Immunologic (pharmacology, therapeutic use)
  • Animals
  • Cell Division (drug effects)
  • Cell Survival (drug effects)
  • Chemotherapy, Adjuvant
  • Cyclophosphamide (pharmacology)
  • Disease Models, Animal
  • Female
  • Male
  • Mice
  • Neoplasms, Experimental (drug therapy)
  • Placebos
  • Pyridines (pharmacology, therapeutic use)
  • Pyrrolidonecarboxylic Acid (analogs & derivatives, pharmacology, therapeutic use)
  • Quaternary Ammonium Compounds (pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: